Sofinnova Venture Partners Ix, L.p. - Net Worth and Insider Trading
Sofinnova Venture Partners Ix, L.p. Net Worth
The estimated net worth of Sofinnova Venture Partners Ix, L.p. is at least $7 Million dollars as of 2024-05-01. Sofinnova Venture Partners Ix, L.p. is the 10% Owner of NextCure Inc and owns about 2,671,856 shares of NextCure Inc (NXTC) stock worth over $4 Million. Sofinnova Venture Partners Ix, L.p. is the 10% Owner of Entasis Therapeutics Holdings Inc and owns about 1,180,178 shares of Entasis Therapeutics Holdings Inc (ETTX) stock worth over $3 Million. Sofinnova Venture Partners Ix, L.p. is also the 10% Owner of Galera Therapeutics Inc and owns about 3,083,712 shares of Galera Therapeutics Inc (GRTX) stock worth over $579,121. Besides these, Sofinnova Venture Partners Ix, L.p. also holds aTyr Pharma Inc (LIFE) , Iterum Therapeutics PLC (ITRM) . Details can be seen in Sofinnova Venture Partners Ix, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Sofinnova Venture Partners Ix, L.p. has not made any transactions after 2020-06-02 and currently still holds the listed stock(s).
Transaction Summary of Sofinnova Venture Partners Ix, L.p.
Sofinnova Venture Partners Ix, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Sofinnova Venture Partners Ix, L.p. owns 6 companies in total, including Checkmate Pharmaceuticals Inc (CMPI) , Iterum Therapeutics PLC (ITRM) , and NextCure Inc (NXTC) among others .
Insider Ownership Summary of Sofinnova Venture Partners Ix, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CMPI | Checkmate Pharmaceuticals Inc | 2020-08-06 | 10 percent owner |
| ITRM | Iterum Therapeutics PLC | 2020-06-02 | 10 percent owner |
| NXTC | NextCure Inc | 2019-11-15 | 10 percent owner |
| GRTX | Galera Therapeutics Inc | 2019-11-12 | 10 percent owner |
| ETTX | Entasis Therapeutics Holdings Inc | 2018-09-28 | 10 percent owner |
| LIFE | aTyr Pharma Inc | 2015-05-12 | 10 percent owner |
Sofinnova Venture Partners Ix, L.p. Latest Holdings Summary
Sofinnova Venture Partners Ix, L.p. currently owns a total of 5 stocks. Among these stocks, Sofinnova Venture Partners Ix, L.p. owns 2,671,856 shares of NextCure Inc (NXTC) as of November 15, 2019, with a value of $4 Million and a weighting of 50.85%. Sofinnova Venture Partners Ix, L.p. owns 1,180,178 shares of Entasis Therapeutics Holdings Inc (ETTX) as of September 28, 2018, with a value of $3 Million and a weighting of 36.35%. Sofinnova Venture Partners Ix, L.p. also owns 3,083,712 shares of Galera Therapeutics Inc (GRTX) as of November 12, 2019, with a value of $579,121 and a weighting of 8.14%. The other 2 stocks aTyr Pharma Inc (LIFE) , Iterum Therapeutics PLC (ITRM) have a combined weighting of 4.66% among all his current holdings.
Latest Holdings of Sofinnova Venture Partners Ix, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NXTC | NextCure Inc | 2019-11-15 | 2,671,856 | 1.35 | 3,615,288 |
| ETTX | Entasis Therapeutics Holdings Inc | 2018-09-28 | 1,180,178 | 2.19 | 2,584,590 |
| GRTX | Galera Therapeutics Inc | 2019-11-12 | 3,083,712 | 0.19 | 579,121 |
| LIFE | aTyr Pharma Inc | 2015-05-12 | 133,296 | 1.59 | 211,954 |
| ITRM | Iterum Therapeutics PLC | 2020-06-02 | 81,768 | 1.46 | 119,381 |
Holding Weightings of Sofinnova Venture Partners Ix, L.p.
Sofinnova Venture Partners Ix, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Sofinnova Venture Partners Ix, L.p. has made a total of 2 transactions in NextCure Inc (NXTC) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in NextCure Inc is the acquisition of 150,000 shares on November 15, 2019, which cost Sofinnova Venture Partners Ix, L.p. around $6 Million.
According to the SEC Form 4 filings, Sofinnova Venture Partners Ix, L.p. has made a total of 0 transactions in Entasis Therapeutics Holdings Inc (ETTX) over the past 5 years. The most-recent trade in Entasis Therapeutics Holdings Inc is the acquisition of 337,724 shares on September 28, 2018, which cost Sofinnova Venture Partners Ix, L.p. around $5 Million.
According to the SEC Form 4 filings, Sofinnova Venture Partners Ix, L.p. has made a total of 1 transactions in Galera Therapeutics Inc (GRTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Galera Therapeutics Inc is the acquisition of 750,000 shares on November 12, 2019, which cost Sofinnova Venture Partners Ix, L.p. around $9 Million.
More details on Sofinnova Venture Partners Ix, L.p.'s insider transactions can be found in the Insider Trading History of Sofinnova Venture Partners Ix, L.p. table.Insider Trading History of Sofinnova Venture Partners Ix, L.p.
- 1
Sofinnova Venture Partners Ix, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Sofinnova Venture Partners Ix, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Sofinnova Venture Partners Ix, L.p. is -4.01%. GuruFocus also compares Sofinnova Venture Partners Ix, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Sofinnova Venture Partners Ix, L.p. within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Sofinnova Venture Partners Ix, L.p.'s insider trading performs compared to the benchmark.
Performance of Sofinnova Venture Partners Ix, L.p.
Average Return
-31.74%
Outperforming Transactions
17%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -9.9 | -4.01 | -9.9 | -31.74 | -52.44 | -48.56 |
| Relative Return to S&P 500(%) | -9.51 | -6.15 | -8.24 | -37.06 | -66.79 | -60.09 |
Sofinnova Venture Partners Ix, L.p. Ownership Network
Ownership Network List of Sofinnova Venture Partners Ix, L.p.
Ownership Network Relation of Sofinnova Venture Partners Ix, L.p.
Sofinnova Venture Partners Ix, L.p. Owned Company Details
What does Checkmate Pharmaceuticals Inc do?
Who are the key executives at Checkmate Pharmaceuticals Inc?
Sofinnova Venture Partners Ix, L.p. is the 10 percent owner of Checkmate Pharmaceuticals Inc. Other key executives at Checkmate Pharmaceuticals Inc include 10 percent owner Venbio Global Strategic Fund Ii L.p. , director & Chief Executive Officer Alan Bash , and 10 percent owner Novo Holdings A/s .
Checkmate Pharmaceuticals Inc (CMPI) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Checkmate Pharmaceuticals Inc (CMPI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Checkmate Pharmaceuticals Inc (CMPI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Checkmate Pharmaceuticals Inc (CMPI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Checkmate Pharmaceuticals Inc Insider Transactions
Sofinnova Venture Partners Ix, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Sofinnova Venture Partners Ix, L.p.. You might contact Sofinnova Venture Partners Ix, L.p. via mailing address: 3000 Sand Hill Road, 4-250, Menlo Park Ca 94025.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
